Continuous estimation of power system inertia using convolutional neural networks.

Inertia is a measure of a power system's capability to counteract frequency disturbances: in conventional power networks, inertia is approximately constant over time, which contributes to network stability. However, as the share of renewable energy sources increases, the inertia associated to synchronous generators declines, which may pose a threat to the overall stability. Reliably estimating the inertia of power systems dominated by inverted-connected sources has therefore become of paramount importance. We develop a framework for the continuous estimation of the inertia in an electric power system, exploiting state-of-the-art artificial intelligence techniques. We perform an in-depth investigation based on power spectra analysis and input-output correlations to explain how the artificial neural network operates in this specific realm, thus shedding light on the input features necessary for proper neural-network training. We validate our approach on a heterogeneous power network comprising synchronous generators, static compensators and converter-interfaced generation: our results highlight how different devices are characterized by distinct spectral footprints - a feature that must be taken into account by transmission system operators when performing online network stability analyses.

Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.

INTRODUCTION: multiple myeloma (MM) is a plasma cell disorder that represents the second most frequent hematologic cancer. Although MM is still an incurable disease, prognosis has improved in the last decades thanks to the introduction of novel agents such as proteasome inhibitors (PIs), immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors. Areas covered: ixazomib is the first oral PI recently approved by Food and Drug Administration (FDA) and European Medicine Agency (EMA) in combination with lenalidomide and dexamethasone as salvage therapy in MM patients. In this paper, we focus on its pharmacokinetics features, as well as its safety and efficacy in clinical studies. Expert opinion: ixazomib can be considered an oral analogue of bortezomib, with 9.5-day half-life, 58% of oral bioavailability, and a large distribution volume of 543L. These features make it a versatile molecule, potentially useful both in combination and as single agent. Oral route of administration and good efficacy/safety profile are its winning characteristics, providing the rationale for a future role also in the maintenance setting.